<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23293">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01803113</url>
  </required_header>
  <id_info>
    <org_study_id>CS-0144-01</org_study_id>
    <nct_id>NCT01803113</nct_id>
  </id_info>
  <brief_title>Sofia hCG FIA Field Study</brief_title>
  <official_title>Sofia hCG FIA Field Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Quidel Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Quidel Corporation</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this field study is to demonstrate the clinical performance of the Sofia
      hCG FIA Test, using urine specimens from females of childbearing age.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects presenting for pregnancy testing will provide urine specimens that will be tested
      with the Sofia hCG FIA test and the comparator pregnancy test that will detect levels of hCG
      of 20mIU as positive for pregnancy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Determination of presence of hCG in urine</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical performance will be based on comparison of Sofia hCG FIA test results to those obtained from an FDA-cleared hCG test.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">975</enrollment>
  <condition>Pregnancy, Early Detection</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sofia hCG FIA</intervention_name>
    <description>Qualitative detection via immunofluorescence technology of increased level of hCG present in urine.</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Leftover urine specimens may be retained to be used for further product testing.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Any female of childbearing potential being screened for pregnancy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female subjects of childbearing age, who are being screened for pregnancy and who
             have signed the informed consent

        Exclusion Criteria:

          -  Subject is post-menopausal.

          -  Subject within the past six weeks has experienced any of the following: delivered a
             newborn; had an abortion or a natural termination (miscarriage); or, received hCG
             supplements.

          -  Subject has had a hysterectomy.

          -  Unable to understand and consent to participation.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Jose Castaneda, MD</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33435-7959</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New England Center for Clinical Research Fall River,LLC (NECCR)</name>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <zip>02720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NECCR of Massachusetts, LLC</name>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <zip>02720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Partners In Obstetrics and Gynecology, Inc.</name>
      <address>
        <city>Pawtucket</city>
        <state>Rhode Island</state>
        <zip>02860</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Planned Parenthood Gulf Coast</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 11, 2013</lastchanged_date>
  <firstreceived_date>February 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pregnancy</keyword>
  <keyword>hCG</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
